Search: onr:"swepub:oai:lup.lub.lu.se:b6ddf8db-a6f6-4f1a-815f-207470930d96" > Montelukast and flu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04354naa a2200469 4500 | |
001 | oai:lup.lub.lu.se:b6ddf8db-a6f6-4f1a-815f-207470930d96 | |
003 | SwePub | |
008 | 160401s2003 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/2984712 URI |
024 | 7 | a https://doi.org/10.1136/bmj.327.7420.8912 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Bjermer, Leifu Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)lung-lbj |
245 | 1 0 | a Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial |
264 | 1 | b BMJ,c 2003 |
338 | a electronic2 rdacarrier | |
520 | a Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Participants Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for greater than or equal to1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of greater than or equal to 12% in FEV1. Main outcome measures The primary end point was the percentage of patients with at least one asthma exacerbation. Results 20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation compared with 19.1% in the group receiving salmeterol and fluticasone; the difference was 1% (95% confidence interval - 3.1% to 5.0%). With a risk ratio (montelukast-fluticasone/ salmeterol-fluticasone) of 1.05 (0.86 to 1.29), treatment with montelukast and fluticasone was shown to be non-inferior to treatment with salmeterol and fluticasone. Salmeterol and fluticasonc significantly increased FEV1 before a beta agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P less than or equal to0.001), whereas FEV1 after a beta agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups. Montelukast and fluticasone significantly (P = 0.011) reduced peripheral blood eosinophil counts compared with salmeterol and fluticasone. Both treatments were generally well tolerated. Conclusion The addition of montelukast in patients whose symptoms remain uncontrolled by inhaled fluticasone could provide equivalent clinical control to salmeterol. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng |
700 | 1 | a Bisgaard, H4 aut |
700 | 1 | a Bousquet, J4 aut |
700 | 1 | a Fabbri, LM4 aut |
700 | 1 | a Greening, AP4 aut |
700 | 1 | a Haahtela, T4 aut |
700 | 1 | a Holgate, ST4 aut |
700 | 1 | a Picado, C4 aut |
700 | 1 | a Menten, J4 aut |
700 | 1 | a Dass, SB4 aut |
700 | 1 | a Leff, JA4 aut |
700 | 1 | a Polos, PG4 aut |
710 | 2 | a Lungmedicin, allergologi och palliativ medicinb Sektion II4 org |
773 | 0 | t BMJ: British Medical Journald : BMJg 327:7420, s. 891-895q 327:7420<891-895x 1756-1833 |
773 | 0 | t BMJd : BMJg 327:7420, s. 891-895q 327:7420<891-895x 0959-8138x 1468-5833 |
856 | 4 | u https://portal.research.lu.se/files/2808626/623879.pdfx primaryx freey FULLTEXT |
856 | 4 | u http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=14563743&dopt=Abstractx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1136/bmj.327.7420.891x freey FULLTEXT |
856 | 4 | u https://www.bmj.com/content/327/7420/891.full.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/298471 |
856 | 4 8 | u https://doi.org/10.1136/bmj.327.7420.891 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.